FCCC LOGO Faculty Publications
Wang L , Li JS , Paskalev K , Hoban P , Luo W , Chen LL , McNeeley S , Price R , Ma C
Commissioning and quality assurance of a commercial stereotactic treatment-planning system for extracranial IMRT
Journal of Applied Clinical Medical Physics. 2006 ;7(1) :21-34
PMID: ISI:000247342900003   
Back to previous list
Abstract
A 3D treatment-planning system (TPS) for stereotactic intensity-modulated radiotherapy (IMRT) using a micro-multileaf collimator has been made available by Radionics. In this work, we report our comprehensive quality assurance (QA) procedure for commissioning this TPS. First, the accuracy of stereotaxy established with a body frame was checked to ensure accurate determination of a target position within the planning system. Second, the CT-to-electron density conversion curve used in the TPS was fitted to our site-specific measurement data to ensure the accuracy of dose calculation and measurement verification in a QA phantom. Using the QA phantom, the radiological path lengths were verified against known geometrical depths to ensure the accuracy of the ray-tracing algorithm. We also checked inter-and intraleaf leakage/transmission for adequate jaw settings. Measurements for dose verification were performed in various head/neck and prostate IMRT treatment plans using the patient-specific optimized fluence maps. Both ion chamber and film were used for point dose and isodose distribution verifications. To ensure that adjacent organs at risk receive dose within the expectation, we used the Monte Carlo method to calculate dose distributions and dose-volume histograms (DVHs) for these organs at risk. The dosimetric accuracy satisfied the published acceptability criteria. The Monte Carlo calculations confirmed the measured dose distributions for target volumes. For organs located on the beam boundary or outside the beam, some differences in the DVHs were noticed. However, the plans calculated by both methods met our clinical criteria. We conclude that the accuracy of the XKnife (TM) RT2 treatment-planning system is adequate for the clinical implementation of stereotactic IMRT.
Notes
ISI Document Delivery No.: 180DW Times Cited: 0 Cited Reference Count: 24 Cited References: BORTFELD T, 1993, MED PHYS, V20, P311 DENG J, 2001, PHYS MED BIOL, V46, P1039 FAIRCLOUGHTOMPA L, 2001, MED DOSIM, V26, P267 FRAASS B, 1998, MED PHYS, V25, P1773 GUNVEN P, 2003, HEPATO-GASTROENTEROL, V50, P1201 HERFARTH KK, 2000, INT J RADIAT ONCOL, V46, P329 HERFARTH KK, 2001, J CLIN ONCOL, V19, P164 HOF H, 2003, INT J RADIAT ONCOL, V56, P335 LAX I, 1994, ACTA ONCOL, V33, P677 LI JS, 2000, PHYS MED BIOL, V45, P2969 LOHR F, 1999, INT J RADIAT ONCOL, V45, P521 MA CM, 2002, PHYS MED BIOL, V47, P1671 MATSUFUJI N, 1998, PHYS MED BIOL, V43, P3261 MORA G, 2003, MED PHYS, V30, P1452 PARKER BC, 2002, J APPL CLIN MED PHYS, V3, P176 PODGORSAK EB, 1999, MODERN TECHNOLOGY RA SHIU AS, 2003, INT J RADIAT ONCOL, V57, P605 TIMMERMAN R, 2003, CHEST, V124, P1946 VANDYK J, 1993, INT J RADIAT ONCOL, V26, P261 VENSELAAR J, 2001, RADIOTHER ONCOL, V60, P191 WANG L, 1998, MED PHYS, V25, P867 WANG L, 1999, MED PHYS, V26, P2626 WANG LB, 2004, J COMPUT CIVIL ENG, V18, P28 WULF J, 2000, RADIOTHER ONCOL, V57, P225